The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Emerging chemotherapy-free approaches in frontline mantle cell lymphoma
Jonathon Cohen, MD, MS, Emory University School of Medicine, Atlanta, GA, discusses emerging approaches that could further reshape frontline treatment for mantle cell lymphoma (MCL). He highlights non-covalent BTK inhibitors, BTK degraders, CAR-T therapy, bispecific antibodies and other targeted therapies as potential options for moving treatment away from chemotherapy. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
